Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary
3.1. Snippet by Action Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Drug Mechanism
3.5. Snippet by Distribution Channel
3.6. Snippet by Region

4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. High prevalence of bacterial diseases such as tuberculosis, chlamydia, and vaginal vaginosis
4.1.1.2. Rising development and commercialization of antibacterial drugs
4.1.2. Restraints
4.1.2.1. Stringent pricing of drugs
4.1.3. Opportunity
4.1.3.1. Increasing number of clinical trials
4.1.4. Impact Analysis

5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Action Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
8.1.2. Market Attractiveness Index, By Action Type
8.2. Bacteriostatic*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Bactericidal

9. By Drug Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.1.2. Market Attractiveness Index, By Drug Type
9.2. Beta-lactams*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Aminoglycosides
9.4. Macrolides
9.5. Quinolones
9.6. Tetracyclines
9.7. Sulfonamide
9.8. Others

10. By Route of Administration
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index, By Route of Administration
10.2. Oral*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Parenteral
10.4. Others

11. By Drug Mechanism
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
11.1.2. Market Attractiveness Index, By Drug Mechanism
11.2. Inhibition of Cell Wall Synthesis*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Inhibition of Protein Synthesis
11.4. Alteration of Cell Membranes
11.5. Inhibition of Nucleic Acid Synthesis
11.6. Antimetabolite Activity

12. By Distribution Channel
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.1.2. Market Attractiveness Index, By End User
12.2. Retail Pharmacies*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Hospital Pharmacies
12.4. Online Pharmacies

13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.8.1. The U.S.
13.2.8.2. Canada
13.2.8.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.8.1. Germany
13.3.8.2. The U.K.
13.3.8.3. France
13.3.8.4. Italy
13.3.8.5. Spain
13.3.8.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.8.1. Brazil
13.4.8.2. Argentina
13.4.8.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.8.1. China
13.5.8.2. India
13.5.8.3. Japan
13.5.8.4. Australia
13.5.8.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
13.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis

15. Company Profiles
15.1. Pfizer Inc.*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Sanofi S.A.
15.3. Bayer AG
15.4. Teva Pharmaceutical Industries Ltd.
15.5. AstraZeneca Plc.
15.6. Novartis AG
15.7. Bristol Myers Squibb Company
15.8. GlaxoSmithKline Plc
15.9. Eli Lilly and Company
15.10. Allecra Therapeutics GmbH(*LIST NOT EXHAUSTIVE)
16. Appendix
16.1. About Us and Services
16.2. Contact Us